Cytokinetics Inc., of South San Francisco, reported additional results from its phase II Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF) trial testing omecamtiv mecarbil in 448 patients with chronic heart failure and left ventricular systolic dysfunction at the Heart Failure Society of America Scientific Meeting in Dallas.